Xenon Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced participation in one-on-one investor meetings and a fireside chat at the 21st Annual Needham (Virtual) Healthcare Conference on April 11, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) has announced participation in one-on-one investor meetings and a fireside chat at the 21st Annual Needham (Virtual) Healthcare Conference on April 11, 2022. The fireside chat will occur from 10:15-10:55 am Eastern Time, featuring Ian Mortimer, President and CEO, and Sherry Aulin, CFO. Recordings of the presentation will be available post-event on their website. The company is dedicated to developing innovative therapies for neurological disorders, particularly focusing on epilepsy.
Details
News Market Reaction – XENE
The recorded move for XENE in the trading session of this news was +2.96%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURNABY, British Columbia, April 04, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat at the 21st Annual Needham (Virtual) Healthcare Conference.
Fireside Chat Details:
| Date: | Monday, April 11, 2022 |
| Time: | 10:15-10:55 am Eastern Time |
| Presenters: | Ian Mortimer, President and CEO; Sherry Aulin, Chief Financial Officer |
Details on company presentations and webcasts can be found on the “Investors” section of Xenon’s website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.